E Ford Model T And Personalized Medicine

While technology marches on, the economics of personalized medicines just don’t add up. Will they be like costly trinkets being displayed in a museum that we can watch at a distance but not own? 

Investors have had lots of gains with CAR-T cell or CRISPR-CAS9 companies such as Juno (JUNO), Kite Pharma (KITE) and Editas (EDIT ).Will patients similarly gain?

1 2
View single page >> |
How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.